Return to Home Incidence > Table

Incidence Rates Table

Data Options
Comparison Options

Incidence Rate Report by State

Melanoma of the Skin (Late Stage^), 2018-2022

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Percentlate

State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late descending
US (SEER+NPCR) 1 3.3 (3.3, 3.3) N/A 13,082 14.4
Minnesota 2 3.6 (3.4, 3.8) 24 (13, 33) 234 9.1
Arizona 2 3.1 (2.9, 3.2) 39 (30, 44) 276 9.4
Maryland 2 2.6 (2.4, 2.8) 48 (43, 50) 190 10.3
Hawaii 7 2.7 (2.4, 3.1) 46 (31, 50) 51 10.8
Utah 7 4.8 (4.4, 5.2) 1 (1, 6) 141 11.3
Idaho 7 3.8 (3.5, 4.2) 15 (3, 32) 81 11.9
Nevada 2 2.7 (2.5, 3.0) 45 (37, 50) 99 11.9
Vermont 2 4.2 (3.6, 4.9) 6 (1, 33) 36 12.0
Georgia 7 3.1 (2.9, 3.2) 40 (31, 44) 356 12.1
North Carolina 2 3.4 (3.3, 3.6) 30 (20, 35) 425 12.2
California 7 2.9 (2.8, 3.0) 41 (38, 45) 1,293 12.4
Iowa 7 4.0 (3.7, 4.3) 12 (3, 25) 153 12.4
Washington 1 3.2 (3.1, 3.4) 33 (25, 40) 286 12.4
Oregon 2 3.1 (2.9, 3.3) 37 (28, 46) 161 12.6
Kansas 2 3.6 (3.3, 3.9) 23 (9, 35) 120 12.7
Nebraska 2 3.7 (3.3, 4.1) 21 (5, 36) 82 13.0
New Jersey 7 2.7 (2.6, 2.8) 47 (41, 50) 311 13.0
South Dakota 2 4.1 (3.5, 4.7) 8 (1, 34) 41 13.0
North Dakota 2 3.8 (3.2, 4.5) 17 (1, 41) 33 13.2
Illinois 7 3.2 (3.0, 3.3) 35 (28, 41) 480 13.5
Maine 2 3.8 (3.4, 4.3) 16 (3, 35) 73 13.8
Wyoming 2 3.8 (3.1, 4.5) 19 (1, 44) 26 14.0
Arkansas 2 3.5 (3.2, 3.8) 28 (12, 38) 127 14.3
Kentucky 7 4.1 (3.9, 4.4) 7 (2, 18) 219 14.3
New York 7 2.5 (2.5, 2.6) 49 (45, 50) 629 14.3
Montana 2 4.0 (3.5, 4.5) 10 (1, 32) 54 14.4
Alaska 2 2.3 (1.8, 2.9) 50 (36, 51) 18 14.7
Florida 2 3.9 (3.8, 4.0) 14 (8, 20) 1,183 14.7
District of Columbia 2 1.5 (1.1, 2.0) 51 (50, 51) 10 14.8
Delaware 2 4.0 (3.5, 4.6) 9 (1, 33) 51 15.1
South Carolina 2 3.4 (3.2, 3.6) 29 (17, 37) 218 15.1
Virginia 2 3.2 (3.1, 3.4) 34 (26, 40) 324 15.1
Louisiana 7 2.8 (2.6, 3.0) 43 (36, 50) 149 15.2
New Hampshire 2 4.4 (3.9, 4.8) 4 (1, 20) 80 15.2
Ohio 2 4.2 (4.1, 4.4) 5 (2, 13) 608 15.6
Alabama 2 3.3 (3.0, 3.5) 32 (22, 41) 199 15.7
New Mexico 7 2.8 (2.5, 3.1) 44 (32, 50) 75 15.8
Wisconsin 2 4.0 (3.8, 4.2) 11 (4, 22) 290 15.9
Connecticut 7 3.1 (2.9, 3.4) 36 (26, 45) 143 16.0
Colorado 2 3.7 (3.5, 3.9) 22 (10, 31) 234 16.4
Michigan 2 3.5 (3.3, 3.7) 25 (17, 33) 431 16.8
Mississippi 2 3.3 (3.0, 3.6) 31 (18, 43) 111 17.0
West Virginia 2 4.4 (4.0, 4.8) 2 (1, 18) 104 17.6
Pennsylvania 2 3.5 (3.4, 3.6) 27 (18, 32) 593 17.7
Oklahoma 2 3.8 (3.5, 4.1) 18 (7, 29) 170 17.9
Missouri 2 3.7 (3.5, 3.9) 20 (9, 29) 272 18.0
Rhode Island 2 3.5 (3.1, 4.0) 26 (7, 44) 49 18.2
Texas 7 2.9 (2.8, 3.0) 42 (39, 46) 845 18.5
Tennessee 2 3.9 (3.7, 4.1) 13 (5, 23) 319 19.1
Massachusetts 2 3.1 (2.9, 3.3) 38 (30, 44) 272 20.0
Puerto Rico 2 0.6 (0.5, 0.7) N/A 30 20.3
Indiana 2 4.4 (4.2, 4.6) 3 (1, 11) 342 21.4

Notes:
Created by statecancerprofiles.cancer.gov on 03/23/2026 12:56 am.

State Cancer Registries may provide more current or more local data.

Trend
Rising when 95% confidence interval of average annual percent change is above 0.
Stable when 95% confidence interval of average annual percent change includes 0.
Falling when 95% confidence interval of average annual percent change is below 0.


† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. The rates used in CI*Rank are all age-adjusted to the 2000 US standard population using 19 age groups for SEER and NPCR areas. More information about methodology can be found on the CI*Rank website.

1 Source: National Program of Cancer Registries and Surveillance, Epidemiology, and End Results SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. Based on the 2024 submission.

2 Source: National Program of Cancer Registries SEER*Stat Database - United States Department of Health and Human Services, Centers for Disease Control and Prevention (based on the 2024 submission).

7 Source: SEER November 2024 submission.

Data for United States does not include Puerto Rico.

CI*Rank data for Puerto Rico is not available.

Return to Top